I previously posted on Sertraline and prostate cancer, but this paper Is hot off the press.
Translational Oncology
Volume 16, February 2022, 101303
Translational Oncology
Sertraline repositioning: an overview of its potential use as a chemotherapeutic agent after four decades of tumor reversal studies
Author links open overlay panelJoão LuizBaú-CarneiroaIsabelaAkemi Guirao SumidaaMaluGallonaTâniaZaleskibcdMariannaBoia-FerreiraeFranceliseBridi Cavassinb
Show more, Share, Cite
doi.org/10.1016/j.tranon.20... rights and content
Under a Creative Commons licenseOpen access
Highlights
•Thirteen different neoplasms were shown to be susceptible to the antidepressant drug sertraline.
•The mechanisms of action through which sertraline can kill tumor cells are apoptosis, autophagy, and drug synergism.
•Sertraline inhibits TCTP, a tumor protein involved in cell survival pathways, responsible for reducing p53 levels.
•The testing of sertraline in vitro and in vivo resulted in reduced cell counting, shrinking of tumoral masses and increased survival rates.
•Dose extrapolation from animals to humans has shown a therapeutic index of sertraline that could support future clinical trials.
Abstract
Sertraline hydrochloride is a first-line antidepressant with potential antineoplastic properties because of its structural similarity with other drugs capable to inhibit the translation-controlled tumor protein (TCTP), a biomolecule involved in cell proliferation. Recent studies suggest it could be repositioned for cancer treatment. In this review, we systematically map the findings that repurpose sertraline as an antitumoral agent, including the mechanisms of action that support this hypotesis. From experimental in vivo and in vitro tumor models of thirteen different types of neoplasms, three mechanisms of action are proposed: apoptosis, autophagy, and drug synergism. The antidepressant is able to inhibit TCTP, modulate chemotherapeutical resistance and exhibit proper cytotoxicity, resulting in reduced cell counting (in vitro) and shrunken tumor masses (in vivo). A mathematical equation determined possible doses to be used in human beings, supporting that sertraline could be explored in clinical trials as a TCTP-inhibitor.